Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Studies from University of California in the area of gene therapy described
December 18th, 2008
According to recent research from the United States, "We have reported a method to target lentiviral vectors to specific cell types. This method requires the incorporation of two distinct molecules on the viral vector surface: one is an antibody that renders the targeting specificity for the engineered vector, and the other is a fusogenic protein that allows the engineered vector to enter the target cell." "However, the molecular mechanism that controls the targeted infection needs to be defined. In this report, we tracked the individual lentiviral particles by labeling the virus with the GFP-Vpr fusion protein. We were able to visualize the surface-displayed proteins...
Source: Gene Therapy Weekly (2008-12-18)
|
